Loading: 100%
Aptevo Therapeutics Inc. logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter , , no data available
Employees 118 (as per Q2 2017)no data available
Sector Biotechnology, HealthcareBiotechnology, Healthcareno data available
Ticker APVOno data available
Financial year endsFY ends End of Decemberno data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 170,000,751,502,253,00
datesClosing price (adj.)
13.10.20172.43
11.10.20172.58
04.10.20172.32
27.09.20172.13
20.09.20172.04
13.09.20171.81
06.09.20171.94
30.08.20171.26
23.08.20171.46
16.08.20171.72
09.08.20171.62
02.08.20171.77
26.07.20171.88
19.07.20171.72
12.07.20171.81
05.07.20172.01
27.06.20172.16
20.06.20172.20
13.06.20172.07
06.06.20172.06
30.05.20172.10
23.05.20172.07
16.05.20172.08
09.05.20172.06
02.05.20172.07
25.04.20171.97
18.04.20171.95
11.04.20171.86
04.04.20171.99
28.03.20171.88
21.03.20171.83
14.03.20171.99
07.03.20171.85
28.02.20172.00
21.02.20172.11
14.02.20171.87
07.02.20171.97
31.01.20171.99
24.01.20172.18
17.01.20172.60
10.01.20172.65
03.01.20172.50
27.12.20162.27
19.12.20161.97
12.12.20161.98
05.12.20161.93
28.11.20161.85
21.11.20162.03
14.11.20162.31
07.11.20161.91
31.10.20162.21
24.10.20162.31
17.10.20162.36
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
2.43n/a
Market Capitalisation
in million USD
52n/a
Enterprise Value
in million USD
0n/a
Common Shares Outstanding
as per Jun 30, 2017
21,309,744n/a
Preferred Shares Outstanding
as per Jun 30, 2017
n/a
Average Basic Shares Outstanding
TTM
20,630,616n/a
Average Diluted Shares Outstanding
TTM
n/a
Index Membership
n/a
Business Summary
Aptevo Therapeutics Inc is a biosciences company. The Company is engaged in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics.
no data available
Key Financials & Ratios (all figures TTM as per , million USD, full statements further below)
Profit & Loss
Revenues 0n/a
Gross Profit 0n/a
Operating Income 0n/a
EBITDA 0n/a
Net Profit 0n/a
Balance Sheet
Cash and Cash Equivalents 0n/a
Receivables 0n/a
Total Current Assets 0n/a
PP&E 0n/a
Total Assets 0n/a
Accounts Payable 0n/a
Current Debt 0n/a
Total Current Liabilities 0n/a
Long-Term Debt 0n/a
Total Liabilities 0n/a
Total Equity 0n/a
Cash Flow
Depreciation & Amortisation 0n/a
Change in Working Capital 0n/a
Operating Cash Flow 0n/a
Net Change in PP&E and Intangibles 0n/a
Investing Cash Flow 0n/a
Dividends Paid 0n/a
Financing Cash Flow 0n/a
Total Change in Cash 0n/a
Free Cash Flow 0n/a
Profitability Ratios
Gross Margin 0.0%n/a
Operating Margin 0.0%n/a
Net Profit Margin 0.0%n/a
Return on Equity 0.0%n/a
Return on Assets 0.0%n/a
Per Share Figures
Basic EPS n/a
Diluted EPS n/a
Sales per Share n/a
Book Value per Share n/a
FCF per Share n/a
Dividends per Share n/a
Price Multiples
Price to Earnings Ratio n/a
Price to Sales Ratio n/a
Price to Book Value n/a
Price to Free Cash Flow n/a
Valuation Metrics
EV/EBITDA n/a
EV/Sales n/a
Book to Market Value n/a
Other Ratios
Current Ratio 0.0%n/a
Liabilities to Equity Ratio 0.0%n/a
Debt to Assets Ratio 0.0%n/a
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (3 items missing)
No data available for the selected time periods
in million USD FY '15FY '16
Product sales
28
36
Collaborations
6
0
Total revenues
34
36
Cost of product sales
17
24
Research and development
35
30
Selling, general and administrative
43
39
Impairment of goodwill and intangible assets
0
71
Loss from operations
-61
-127
Other income (expense), net
0
-1
Total other income (expense), net
0
-1
Loss before benefit from income taxes
-61
-128
Benefit from income taxes
2
15
Benefit from income taxes
-59
-112
Remarks
restated on Mar 31, 2017 n/a
calculated values,
restated on Mar 31, 2017 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (9 items missing)
No data available for the selected time periods
in million USD FY '15FY '16
Assets
Cash and cash equivalents
5
10
Restricted cash
0
0
Accounts receivable, net
6
4
Short-term investments
0
45
Inventories
20
7
Income tax receivable, net
1
0
Prepaid expenses and other current assets
2
6
Total current assets
35
71
Property and equipment, net
4
6
In-process research and development
42
0
Intangible assets, net
17
15
Goodwill
29
0
Total assets
128
92
Liabilities and owners' equity
Accounts payable
10 10084000
11 11489000
Accrued compensation
3 3334000
4 4009000
Contingent consideration, current portion
0 444000
0 0
Sales rebates and discounts
2 2238000
3 3235000
Deferred revenue, current portion
4 3843000
1 811000
Total current liabilities
20 19943000
20 19544000
Deferred revenue, net of current portion
3 3318000
3 2896000
Long-term debt, net
0 0
18 18383000
Deferred income taxes
16 15817000
0 0
Other liabilities
0 71000
0 469000
Total liabilities
39 39149000
41 41292000
Parent investment in subsidiary
321 320606000
0 0
Accumulated deficit
-232 -231988000
-81 -80692000
Preferred stock
0 0
0 0
Common stock
0 0
0 20000
Additional paid-in capital
0 0
151 151271000
Accumulated other comprehensive income
0 0
0 -33000
Contribution receivable from former parent
0 0
-20 -20000000
Total stockholders' equity
89 88618000
51 50566000
Total liabilities and stockholders' equity
128 127767000
92 91858000
Remarks restated on Mar 31, 2017 n/a restated on Aug 10, 2017 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (17 items missing)
No data available for the selected time periods
in million USD FY '15FY '16
Net loss
-59
-112
Net loss
1
4
Amortization of intangible assets
-1
-16
Income taxes
0
0
Changes in fair value of contingent consideration
3
3
Depreciation and amortization
4
2
Accounts receivable
0
71
Impairment of goodwill and intangible assets
-3
14
Inventories
0
0
Restricted cash
3
0
Income taxes
3
-3
Provision for allowance for doubtful accounts
0
1
Prepaid expenses and other current assets
-2
2
Other liabilities
0
1
Accrued compensation
3
-3
Sales rebates and discounts
-49
-37
Deferred revenue
-2
-3
Net cash used in operating activities
0
-45
Purchases of investments
-2
-47
Payments for taxes related to net share settlement of equity awards
52
71
Payment from former parent upon spin-off, net of receivable
0
0
Settlement of contribution receivable from former parent
-1
0
Common stock issued upon exercise of stock options
0
0
Contingent consideration payments
0
-2
Common stock issued upon vesting of restricted stock units
0
20
Debt issuance costs
51
89
Proceeds from long-term debt
1
5
Remarks
restated on Mar 31, 2017 n/a
calculated values,
restated on Mar 31, 2017 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
Sumo